Skip to content
  • People
  • Pipeline
  • Publications
  • News
  • Blogs
  • People
  • Pipeline
  • Publications
  • News
  • Blogs
  • People
  • Pipeline
  • Publications
  • News
  • Blogs
  • Contact us
  • People
  • Pipeline
  • Publications
  • News
  • Blogs
  • Contact us
Contact

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA

April 11, 2022

Our CEO Jennifer Barnett will be speaking at the Neuroimmunology Drug Development Summit, taking place next week in Boston, MA.

Don’t miss her in-person talk:
Using Digital Biomarkers to Apply a Stratified Approach to Neuroinflammation
When: April 19th, 9AM EST

Synopsis

  • Applying digital biomarkers, in combination with standard inflammatory markers, to aid identification of people at high risk for neuroinflammation
  • Using prophylactic small molecule approach for neuroinflammation to analyze neuroinflammatory outcomes in patients with post-operative cognitive decline in
  • Referencing the outcomes of the clinical trials conducted by Monument Tx to outline the above

Can’t attend the event but want to learn more our work applying digital biomarkers to aid identification of people at high risk for #neuroinflammation? Contact us directly: info@monumenttx.com

For further information, contact:

Jenny Barnett, CEO

E: jbarnett@monumenttx.com

PrevOlder
NewerNext

Bringing Precision Medicine to Neuroscience Drug Development

MT LOGO WHITE PNG-01
info@monumenttx.com
Get in touch
© Copyright 2026  |  Privacy Policy & Terms of Use